Anti-myelin-associated glycoprotein (Anti-MAG) neuropathy and autoimmune nodopathies with antibodies targeting nodal or paranodal proteins have recently been reclassified as distinct conditions, separate from chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). This distinction is based on the clinical homogeneity observed in antibody-positive cases, their unique response to treatment compared to CIDP, and evidence indicating the pathogenic role of these autoantibodies. The significance of identifying conditions outside the CIDP category lies in the elucidation of their distinct pathological mechanisms and providing appropriate immunotherapy accordingly. We hope that the various pathologies currently grouped under CIDP will be further clarified in the future, leading to the elimination of CIDP variants with different pathophysiologies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.11477/mf.188160960770010035 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!